Biomarkers beyond BRCA: promising combinatorial treatment strategies in overcoming resistance to PARP inhibitors
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1423-0127
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Biomarkers beyond BRCA: promising combinatorial treatment strategies in overcoming resistance to PARP inhibitors ; volume:29 ; number:1 ; day:25 ; month:10 ; year:2022 ; pages:1-13 ; date:12.2022
Journal of biomedical science ; 29, Heft 1 (25.10.2022), 1-13, 12.2022
- Creator
-
Chu, Yu-Yi
Yam, Clinton
Yamaguchi, Hirohito
Hung, Mien-Chie
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12929-022-00870-7
- URN
-
urn:nbn:de:101:1-2023011021083843630498
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:37 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Chu, Yu-Yi
- Yam, Clinton
- Yamaguchi, Hirohito
- Hung, Mien-Chie
- SpringerLink (Online service)
Other Objects (12)
Overcoming PARP inhibitor resistance in ovarian cancer: what are the most promising strategies?
Fortgeschrittenes Mammakarzinom: Therapie mit PARP-Inhibitoren und Relevanz der BRCA-Diagnostik
Chlorambucil targets BRCA 1/2‐deficient tumours and counteracts PARP inhibitor resistance
VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status
A RAD 51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation
Nucleolytic processing of abasic sites underlies PARP inhibitor hypersensitivity in ALC1-deficient BRCA mutant cancer cells
STING agonism enhances anti-tumor immune responses and therapeutic efficacy of PARP inhibition in BRCA-associated breast cancer
Pharmacodynamic effects of the PARP inhibitor talazoparib (MDV3800, BMN 673) in patients with BRCA-mutated advanced solid tumors
Schlafen 11 further sensitizes BRCA-deficient cells to PARP inhibitors through single-strand DNA gap accumulation behind replication forks
PARP inhibitors
New combinatorial strategies to improve the PARP inhibitors efficacy in the urothelial bladder Cancer treatment
MiR-181a targets STING to drive PARP inhibitor resistance in BRCA- mutated triple-negative breast cancer and ovarian cancer
Overcoming PARP inhibitor resistance in ovarian cancer: what are the most promising strategies?
Fortgeschrittenes Mammakarzinom: Therapie mit PARP-Inhibitoren und Relevanz der BRCA-Diagnostik
Chlorambucil targets BRCA 1/2‐deficient tumours and counteracts PARP inhibitor resistance
VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status
A RAD 51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation
Nucleolytic processing of abasic sites underlies PARP inhibitor hypersensitivity in ALC1-deficient BRCA mutant cancer cells
STING agonism enhances anti-tumor immune responses and therapeutic efficacy of PARP inhibition in BRCA-associated breast cancer
Pharmacodynamic effects of the PARP inhibitor talazoparib (MDV3800, BMN 673) in patients with BRCA-mutated advanced solid tumors
Schlafen 11 further sensitizes BRCA-deficient cells to PARP inhibitors through single-strand DNA gap accumulation behind replication forks
PARP inhibitors
New combinatorial strategies to improve the PARP inhibitors efficacy in the urothelial bladder Cancer treatment
MiR-181a targets STING to drive PARP inhibitor resistance in BRCA- mutated triple-negative breast cancer and ovarian cancer
Overcoming PARP inhibitor resistance in ovarian cancer: what are the most promising strategies?
Fortgeschrittenes Mammakarzinom: Therapie mit PARP-Inhibitoren und Relevanz der BRCA-Diagnostik
Chlorambucil targets BRCA 1/2‐deficient tumours and counteracts PARP inhibitor resistance
VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status
A RAD 51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation
Nucleolytic processing of abasic sites underlies PARP inhibitor hypersensitivity in ALC1-deficient BRCA mutant cancer cells
STING agonism enhances anti-tumor immune responses and therapeutic efficacy of PARP inhibition in BRCA-associated breast cancer
Pharmacodynamic effects of the PARP inhibitor talazoparib (MDV3800, BMN 673) in patients with BRCA-mutated advanced solid tumors
Schlafen 11 further sensitizes BRCA-deficient cells to PARP inhibitors through single-strand DNA gap accumulation behind replication forks
PARP inhibitors
New combinatorial strategies to improve the PARP inhibitors efficacy in the urothelial bladder Cancer treatment